Welcome to our dedicated page for Cytokinetics SEC filings (Ticker: CYTK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cytokinetics, Incorporated filings document a specialty cardiovascular biopharmaceutical company with common stock listed on the Nasdaq Global Select Market. Its 8-K reports cover financial results, corporate presentations, MYQORZO® regulatory approvals, clinical and regulatory disclosures, and material capital-structure events such as underwriting agreements for common stock offerings.
Proxy materials describe board elections, executive compensation, auditor ratification and equity plan amendments, including matters tied to the company’s employee stock purchase plan. Other filings address governance changes, risk disclosures, registered securities, exhibits and Inline XBRL cover-page data associated with Cytokinetics’ public-company reporting obligations.
Cytokinetics director John T. Henderson reported receiving 334 shares of Cytokinetics common stock on 01/15/2026 at a value of $63.44 per share. These fully vested shares were issued in lieu of a cash retainer under the company’s Equity in Lieu of Cash Retainer Option available to members of the Board of Directors.
After this award, Henderson beneficially owned 74,912 shares of Cytokinetics common stock directly, and an additional 83 shares indirectly through his spouse. This filing reflects routine equity compensation for board service rather than an open-market share purchase.
Cytokinetics director Robert Arthur Harrington reported receiving additional company stock as compensation. On January 15, 2026, he acquired 197 shares of Cytokinetics common stock at $63.44 per share. These were fully vested shares received in lieu of a cash retainer under an equity compensation option available to members of the Board of Directors.
Following this transaction, Harrington beneficially owned 18,739 shares of Cytokinetics common stock in direct ownership. The filing reflects routine director compensation paid in stock rather than cash, with no sales reported.
Cytokinetics executive Dr. Malik, EVP of Research & Development, reported insider transactions dated 12/16/2025. The disclosure shows an exercise of 2,200 incentive stock options at $10.60 per share, creating 2,200 shares of common stock, followed by a same-day sale of 2,200 common shares at $61.24 per share. After these transactions, Dr. Malik directly beneficially owns 138,552 shares of Cytokinetics common stock.
Cytokinetics, Incorporated reported that the European Medicines Agency’s Committee for Medicinal Products for Human Use adopted a positive opinion recommending marketing authorization in the European Union for MYQORZO® (aficamten). The medicine is a cardiac myosin inhibitor intended to treat symptomatic New York Heart Association (NYHA) class II–III obstructive hypertrophic cardiomyopathy in adult patients.
The company stated that a final decision from the European Commission on this marketing application is anticipated in the first quarter of 2026. It also highlighted that statements about potential approval are forward-looking and that actual outcomes may differ from these expectations.
Cytokinetics, Inc. reported an insider stock transaction by its President & CEO and Director on 12/03/2025. The filing shows the disposition of 5,930 shares of common stock at a price of $65.02 per share, recorded under transaction code F.
After this transaction, the reporting person directly beneficially owns 350,202 shares of Cytokinetics common stock. In addition, the filing notes indirect ownership of 2,083 shares held by The Bridget Blum 2003 Irrevocable Trust and 2,083 shares held by The Brittany Blum 2003 Irrevocable Trust.
CYTOKINETICS, INC. (CYTK) reported an insider stock sale by a director. On 11/19/2025, the director sold 5,000 shares of common stock in an open market transaction coded as a sale at a price of $64.73 per share. After this transaction, the director beneficially owns 22,933 shares of CYTOKINETICS common stock in direct ownership. The filing is signed by an attorney-in-fact on behalf of the reporting person.
Cytokinetics (CYTK) Form 4 discloses an insider stock option exercise and sale by an executive. The company’s Executive Vice President of Research & Development reported exercising stock options for 2,200 shares of common stock at a price of $10.60 per share on 11/18/2025, then selling 2,200 shares of common stock the same day at a price of $66.45 per share.
After these transactions, the executive directly beneficially owned 140,610 shares of Cytokinetics common stock and held 4,400 derivative securities (stock options) following the reported activity. The filing is made by a single reporting person and is a routine disclosure of insider equity transactions.
Cytokinetics, Inc. (CYTK) reported an equity award to its Chief Legal & Admin Officer, Mr. Hessekiel. On 11/14/2025, he received an initial new hire grant of 87,297 restricted stock units (RSUs) of common stock at a price of $0 per share, all held as direct ownership after the transaction.
The RSUs convert into common stock on a 1:1 basis as they vest. The vesting schedule is staggered over three years: 40% of the RSUs vest one year from the grant date, another 40% vest two years from the grant date, and the remaining 20% vest three years from the grant date, in each case conditioned on his continued employment with Cytokinetics.
Cytokinetics appointed Jeffrey J. Hessekiel as Executive Vice President, Chief Legal and Administrative Officer, effective November 14, 2025. His compensation includes a $660,000 annual base salary, a target bonus equal to 50% of salary (75% tied to corporate goals and 25% to individual goals), and a $400,000 signing bonus split into two equal payments, with the initial portion subject to repayment if he resigns or is terminated for cause within one year.
As an inducement equity grant, he will receive restricted stock units with a grant date value of $5,800,000, vesting 40% on the first anniversary, 40% on the second, and 20% on the third, subject to continued service and potential acceleration under the company’s Executive Severance Plan. He will participate in Cytokinetics’ standard benefit, bonus, equity, and severance programs and has entered into the company’s standard indemnification agreement.
Cytokinetics (CYTK) filed a Form 4 reporting insider activity. On 11/11/2025, a director exercised 5,175 stock options at $9.66 per share (code M), then sold 5,175 shares at $65.08 (code S). After these transactions, the director beneficially owned 9,977 shares, held directly.
The exercised options were non-qualified options originally exercisable beginning 08/01/2016 and expiring 07/01/2026, covering 5,175 underlying common shares.